The Rising Threat of Chikungunya: A Global Health Concern and the Race for a Vaccine
In Australia, the number of Chikungunya cases is on the rise, and with a potential vaccine on the horizon, this mosquito-borne virus is gaining attention. But here's where it gets controversial: while the virus is not yet endemic in Australia, the increasing number of infections among international travelers and the presence of mosquito vectors in the north pose a real threat.
According to the Australian Centre for Disease Control, the number of Chikungunya cases in 2025 has skyrocketed to 165, a significant jump from the 69 cases reported in 2024. Victoria takes the lead with 80 cases, followed by NSW and Western Australia. This surge in cases has sparked concern among health experts and researchers.
Chikungunya, a virus that primarily targets joint tissue, muscle fibers, and connective tissue, causes intense inflammation and tissue damage. Symptoms include fever, severe joint and muscle pain, headaches, rashes, and joint swelling. The virus poses a greater risk to older adults, individuals with underlying conditions, and newborns, with rare cases leading to severe illness in infants during pregnancy.
Currently, there is no specific antiviral treatment, and management focuses on supportive care. However, the real worry lies in the potential for local transmission. Although the Chikungunya virus has not been detected in Australian mosquitoes, the primary mosquito vectors are present in northern Queensland and the Torres Strait, creating a high risk of spread if the virus is introduced.
Associate Professor Cameron Webb, a mosquito expert and principal hospital scientist, sheds light on the situation. He emphasizes that most cases are acquired overseas, with only a few in North Queensland. Australians' increasing travel to tropical destinations where these viruses are active, coupled with the rising activity of these viruses worldwide, contributes to the spread.
Professor Webb highlights a unique behavior of the mosquitoes carrying the Chikungunya virus. Unlike typical Australian mosquitoes, these mosquitoes prefer to bite during the day, often catching people off guard. The high concentration of these mosquitoes in popular holiday destinations like Indonesia, Southeast Asia, and the Pacific, makes travelers particularly vulnerable.
So, what can be done to protect against these sneaky mosquitoes? Professor Webb recommends using a quality mosquito repellent throughout the day. He advises travelers to bring their own repellent from Australia, ensuring its safety and effectiveness. Applying repellent routinely when going outdoors provides the best protection, especially as these mosquitoes tend to feed around the feet and lower legs.
In a promising development, researchers at Queensland's Griffith University are making significant progress towards a Chikungunya vaccine. Led by Professor Bernd Rehm, the team has engineered Escherichia coli to create synthetic biopolymer particles that mimic the surface of the Chikungunya virus. In preclinical studies, these particles successfully induced a protective immune response without the need for an adjuvant.
The experimental vaccine, known as adjuvant-free E2-BP-E1 biopolymer particles, displays Chikungunya antigens in a structure similar to the native virus. This design allows immune cells to recognize and absorb the particles efficiently, triggering a robust antiviral response without causing infection. Professor Rehm explains, "The immune system recognizes the particles as a virus but without inducing infection, prompting a protective response."
One of the key concerns with Chikungunya is the high rate of chronic morbidity. Up to 60% of patients experience persistent joint pain that can last for months or even years, often resembling rheumatoid arthritis. Professor Rehm suggests that immune-mediated damage may continue even after the virus is cleared, leading to long-term health issues.
Following the success of their current study, the Griffith team plans to move the vaccine into clinical development. The next phase will involve early-stage clinical trials to assess safety, followed by efficacy studies. The findings have been published in the journal Biomaterials, offering hope for a potential solution to this global health threat.
As the race for a Chikungunya vaccine continues, it's essential to stay informed and take necessary precautions when traveling to areas where these viruses are active. With the right measures, we can protect ourselves and contribute to the global effort to control this emerging health concern.
What are your thoughts on the rising Chikungunya cases and the potential vaccine? Do you think enough is being done to raise awareness and prevent the spread of this virus? Share your thoughts in the comments below!
